公开(公告)号：US20230416221A1

公开(公告)日：2023-12-28

申请号：US18038126

申请日：2021-10-21

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Qingsong LIU ,  Jing LIU ,  Yun WU ,  Beilei WANG ,  Aoli WANG ,  Chen HU ,  Qingwang LIU ,  Fengming ZOU ,  Wenchao WANG ,  Zuowei WANG ,  Jiangyan CAO ,  Chenliang SHI ,  Li WANG

IPC: C07D401/04 ,  C07D403/04 ,  C07D401/14 ,  A61P35/00

CPC classification number: C07D401/04 ,  A61P35/00 ,  C07D401/14 ,  C07D403/04

Abstract: A kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. A method and a use for using the inhibitor for treatment of diseases related to CDK9 and/or mutagenic activity thereof.

公开(公告)号：US20210346406A1

公开(公告)日：2021-11-11

申请号：US17283646

申请日：2019-10-09

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Qingsong LIU ,  Jing LIU ,  Yun WU ,  Wenliang WANG ,  Beilei WANG ,  ZiPing QI ,  Junjie WANG ,  Wenchao WANG ,  Shuang QI ,  Li WANG

IPC: A61K31/635 ,  C07D475/00 ,  C07D475/12 ,  A61K31/519 ,  A61K31/5377 ,  A61P1/16 ,  A61P3/10

Abstract: Disclosed is a kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite, or prodrug thereof. Also disclosed are a pharmaceutical composition comprising the kinase inhibitor and uses and methods for inhibiting the activity of one or more tyrosine kinases selected from MST1 and a mutant thereof in a cell or subject and for preventing or treating a disease related to MST1 or a mutant thereof in a subject by using the compound or composition.

公开(公告)号：US20200323850A1

公开(公告)日：2020-10-15

申请号：US16956860

申请日：2017-12-26

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Qingsong LIU ,  Jing LIU ,  Xiaofei LIANG ,  Beilei WANG ,  Kailin YU ,  Zongru JIANG ,  Cheng CHEN ,  Chen HU ,  Wenchao WANG ,  Fengming ZOU ,  Qingwang LIU ,  Feng LI ,  Wenliang WANG ,  Li WANG

IPC: A61K31/505 ,  A61P35/02 ,  C07D239/47 ,  C07D405/12 ,  A61K31/506 ,  C07D403/12 ,  C07D403/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  A61K31/5377

Abstract: The present invention relates to a kinase inhibitor, comprising a compound of Formula I or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also relates to a pharmaceutical composition comprising the kinase inhibitor, and to uses and methods for using these compounds and compositions to inhibit the activity of wild-type FLT3, mutant FLT3-ITD, PDGFRα and/or PDGFRβ kinase in a cell or a subject, as well as uses and methods of these compounds and compositions to preventing or treating kinase-associated conditions in a subject.

公开(公告)号：US20190040013A1

公开(公告)日：2019-02-07

申请号：US16074970

申请日：2016-12-22

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES

Inventor： Jing LIU ,  Qingsong LIU ,  Qianmao LIANG ,  Yongfei CHEN ,  Cheng CHEN ,  Aoli WANG ,  Hong WU ,  Kailin YU ,  Wei WANG ,  Chen HU ,  Wenchao WANG ,  Shuang QI ,  Beilei WANG ,  Li WANG

IPC: C07D213/74 ,  C07D405/12 ,  C07D401/12 ,  C07D409/12

Abstract: The present invention provides an inhibitor of Bruton's tyrosine kinase, which is a compound of formula (I), or its pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method for inhibiting the activity of tyrosine kinase activity or for treating a disease, disorder, or condition, which would benefit from the inhibition of Bruton's tyrosine kinase(s), by using the Bruton's tyrosine kinase inhibitor, as well application of the Bruton's tyrosine kinase inhibitor for the same.

公开(公告)号：US20180030054A1

公开(公告)日：2018-02-01

申请号：US15544676

申请日：2015-08-07

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES ,  HEFEI COSOURCE PHARMACEUTICAL CO., LTD.

Inventor： Jing LIU ,  Qingsong LIU ,  Xixiang LI ,  Aoli WANG ,  Hong WU ,  Cheng CHEN ,  Wenchao WANG ,  Chen HU ,  Zheng ZHAO ,  Jiaxin WU ,  Juan LIU ,  Kailin YU ,  Wei WANG ,  Li WANG ,  Beilei WANG

IPC: C07D487/04 ,  A61K31/5377 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377

Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).

公开(公告)号：US20170128439A1

公开(公告)日：2017-05-11

申请号：US15320120

申请日：2015-01-27

Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES ,  ANHUI NEW STAR PHARMCEUTICAL DEVELOPMENT CO., LTD.

Inventor： Qingsong LIU ,  Jing LIU ,  Yongfei CHEN ,  Hong WU ,  Aoli WANG ,  Beilei WANG ,  Chen HU ,  Wenchao WANG ,  Cheng CHEN

IPC: A61K31/4745 ,  C07D471/04

CPC classification number: A61K31/4745 ,  C07D471/04

Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.